首页|期刊导航|Oncology Research|Autocrine Motility Factor-Derived Tetradecapeptides as Dual-Action Chemosensitizers:Bridging Cell Competition Mechanisms with Clinical MDR Reversal in Hematological Malignancies

Autocrine Motility Factor-Derived Tetradecapeptides as Dual-Action Chemosensitizers:Bridging Cell Competition Mechanisms with Clinical MDR Reversal in Hematological Malignancies

Changyul Kim Yu Ju Jung Da Hee Son Na Young Kim Se Gie Kim Hee Sung Park

Oncology Research2026，Vol.34Issue(7)：P.416-433,18.

Oncology Research2026，Vol.34Issue(7)：P.416-433,18.DOI:10.32604/or.2026.078448

Autocrine Motility Factor-Derived Tetradecapeptides as Dual-Action Chemosensitizers:Bridging Cell Competition Mechanisms with Clinical MDR Reversal in Hematological Malignancies

Changyul Kim ¹Yu Ju Jung ²Da Hee Son ²Na Young Kim ²Se Gie Kim ³Hee Sung Park⁴

作者信息

1. Department of Health Management,Daegu Catholic University,Gyeongsan,Republic of Korea Department of Toxicology,Daegu Catholic University,Gyeongsan,Republic of Korea
2. Department of Toxicology,Daegu Catholic University,Gyeongsan,Republic of Korea
3. Department of Cosmetic Science,Kyungsung University,Busan,Republic of Korea
4. Department of Health Management,Daegu Catholic University,Gyeongsan,Republic of Korea
折叠

摘要

关键词

Autocrine motility factor peptide/drug retention/hematological malignancy/multidrug resistance protein 1(MDR1)/multidrug resistance-associated protein 1(MRP1)

分类

医药卫生

引用本文复制引用

Changyul Kim,Yu Ju Jung,Da Hee Son,Na Young Kim,Se Gie Kim,Hee Sung Park..Autocrine Motility Factor-Derived Tetradecapeptides as Dual-Action Chemosensitizers:Bridging Cell Competition Mechanisms with Clinical MDR Reversal in Hematological Malignancies[J].Oncology Research,2026,34(7):P.416-433,18.

基金项目

supported by the National Research Foundation of Korea(NRF)Grant funded by the Korea Government(MSIT)(2022R1I1A1A01063465). （NRF）

Oncology Research

ISSN：0965-0407

访问量0

下载量0

段落导航